CENTOGENE Receives Delisting Notice From Nasdaq, Effective At The Open Of Trading On August 8, 2024
CENTOGENE Receives Delisting Notice From Nasdaq, Effective At The Open Of Trading On August 8, 2024
Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notice from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist CENTOGENE'S common stock from Nasdaq. The notice indicates that CENTOGENE (the "Company") remains noncompliant with Nasdaq Listing Rule 5450(b)(2)(C), which requires a minimum USD 15 million market value of publicly held shares.
作为罕见病与神经退行性疾病数据驱动答案的重要生命科学合作伙伴，Centogene N.V.今天宣布，它收到了纳斯达克证券交易所（"Nasdaq"）的通知，指示纳斯达克听证会已决定从纳斯达克摘牌CENTOGENE的普通股。该通知指出，公司CENTOGENE仍未遵守纳斯达克上市规则5450(b)(2)(C)，该规则要求公开持股的最小市值为1500万美元。
Suspension of trading in the Company's common stock on Nasdaq will be effective at the open of trading on August 8, 2024. The Company may, within 15 calendar days from the date of the notice, request that Nasdaq review the decision, but the Company does not intend to make such a request.
公司的普通股在纳斯达克停牌的时间将从2024年8月8日交易开始时生效。公司在通知日期起15个日历日内可以请求纳斯达克审查该决定，但公司没有这样的意向。
